Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Addgene is open for ordering and depositing; find up-to-date details here. To learn more about how we are supporting COVID-19 research and to find related plasmids, check out our COVID-19 and Coronavirus Plasmids & Resources page.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

Rett Syndrome Plasmid Collection and Resource Center



The Rett Syndrome Research Trust (RSRT) was launched in 2008 to drive the development of treatments and cures for Rett Syndrome and related MECP2 disorders. The RSRT has a comprehensive, strategic and aggressive plan to use gene editing, MECP2 reactivation, RNA editing, gene replacement therapy, RNA trans-splicing, and protein replacement to reverse the impacts of this disease. Addgene is working with the RSRT along with individual laboratories to assemble a Rett Syndrome plasmid resource for the scientific research community.

Background

Rett Syndrome

Rett syndrome is a neurodevelopmental disorder that presents in early toddlerhood primarily affecting females at an incidence of approximately 1:10,000. It is characterized by apparently normal development through the first 6 months of age, followed by developmental delay between 6 and 18 months of age. A defining feature, with onset typically between 18 to 30 months, is regression of previously acquired skills, notably loss of acquired purposeful hand movements and regression of speech. In contrast to the sustained loss of skills in neurodegenerative conditions, the regressive period in Rett syndrome is self-limited, after which a period of developmental stabilization or even limited recovery of skills occurs.

Diagnosis of Rett syndrome is currently based on specific clinical diagnostic criteria, defined as the presence of relatively normal early development, regression with a loss of spoken language and hand skills, development of repetitive hand stereotypies, and gait dysfunction or absence of gait. Greater than 95% of individuals who meet diagnostic criteria have disease-causing mutations in the gene methyl-CpG binding protein 2 (MECP2).

MECP2

Rett syndrome is an X-linked disorder caused from loss-of-function mutations in the MECP2 gene. Causative mutations for Rett syndrome typically arise spontaneously, although in rare cases Rett syndrome can be inherited. In females, random X inactivation results in approximately half of cells expressing wild-type MECP2 and half expressing mutant MECP2. Skewing of these X inactivation ratios can affect disease severity.

The MECP2 protein is a global transcriptional regulator of thousands of genes and studies have suggested roles in transcriptional repression, activity dependent de-repression, chromatin remodeling, gene activation, and more. How loss of MECP2 protein function results in Rett syndrome is not clear, however, the ability to bind to methylated DNA and recruit known co-repressors or other transcriptional modifiers suggests the major function of MECP2 is to regulate gene expression either locally or globally.

The MECP2 protein contains several functional domains, including:

  • the N-terminal Domain (NTD)
  • the Methyl Binding Domain (MBD)
  • a Transcriptional Repressor Domain (TRD)
    • the TRD contains a Nuclear receptor Co-Repressor 1/Silencing Mediator of Retinoic acid and Thyroid hormone receptor (NCoR/SMRT) interacting domain (NID)
    • a nuclear localization signal (not essential for localization)
  • the C-terminal Domain (CTD)

The most common missense mutations cluster in the MBD and NID demonstrating the importance of binding to methylated DNA and the recruitment of the NCoR complex for proper nervous system function.

While there is wide variability in symptoms even within patients with the same mutation, the location and type of MECP2 mutation can be a strong predictor of symptom severity. Broadly, early gene disruptions, missense mutations located in the MBD, and truncations prior to the NID are more severe than mutations further downstream in the NID and C-terminus. A large number of mutations are known to cause Rett syndrome, however, eight recurrent missense and nonsense mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C) account for almost 46% of all Rett syndrome cases.

Research Milestones

  • 1992 - MECP2 is discovered by Adrian Bird's lab. PMID: 1606614
  • 1999 - Huda Zoghbi's lab identifies MECP2 as the genetic cause of RTT. PMID: 10508514
  • 2007 - Adrian Bird's lab demonstrates that Rett syndrome symptoms are reversible in mice if MECP2 gene expression is switched on regardless of age or symptom severity, suggesting that restoring MECP2 expression in humans could be curative. PMID: 17289941
  • 2010 - Allyson Muotri's lab develops the first iPSC model for Rett syndrome. PMID: 21074045
  • 2017 - the Bird lab determines a minimally functional MECP2 that rescues neurological defects of Rett syndrome. PMID: 29019980

Return to top

Animal Models

Studies of the MECP2 protein in mouse and rat models have accelerated our understanding of Rett syndrome at the molecular level. They are also an important tool for developing therapeutic strategies to treat Rett syndrome and restore functional MECP2 in cells.

  • Search JAX Mice for mouse models that include MECP2 null alleles or common mutations that recapitulate Rett syndrome in humans.
  • MECP2 knockout rats are available from Envigo.

Human Cell Line Models

Induced pluripotent stem cells (iPSCs) are a powerful system for generating Rett syndrome-specific differentiated cells that can be used to understand the mechanisms of the disease and for the development of successful therapeutics.

For more information on generating iPSCs using plasmids, please see Addgene's Plasmids for Stem Cell Research page.

CRISPR Tools

CRISPR technology is a promising therapeutic approach for precise editing of mutations in the MECP2 gene. Please refer to Addgene's CRISPR Guide for a general introduction to CRISPR technology or the mammalian CRISPR resources for a full selection of plasmids expressing Cas9 and empty gRNA backbones. A few examples of additional CRISPR resources can be found below:

Plasmids

MECP2 Plasmids

The table below highlights plasmids that express the MECP2 gene. Use the search bar or sort buttons to find plasmids based on:

  • Expression system (mammalian or bacterial)
  • Insert species (mouse or human)
  • Mutation
ID Plasmid Description Gene/Insert Mutations PI

Return to top

External Resources

Research Databases

  • InterRett - international online database of clinical features and genetic characteristics of Rett syndrome
  • RettBase - MECP2 mutation database
  • OMIM Rett Syndrome - Rett syndrome curated literature information
  • OMIM MECP2 - MECP2 curated literature information
  • UniProt MECP2 - MECP2 curated protein and functional information
  • Meta Rett Syndrome feed - Addgene is pleased to collaborate with Meta to provide a curated list of articles and preprints on Rett syndrome. Click on the link to see the top 20 new and impactful papers.

Mouse and Cell Line Repositories

Tissue Banks

Antibodies

Additional Resources

Funding Opportunities

References

Amir et al. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 23, 185–188. PMID: 10508514

Archer et al. 2007. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet. 44, 148–152. PMID: 16905679

Cuddapah et al. 2014. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 51, 152–158. PMID: 24399845

Guy et al. 2007. Reversal of Neurological Defects in a Mouse Model of Rett Syndrome. Science. 315, 1143–1147. PMID: 17289941

Hagberg et al. 1983. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol. 14, 471–479. PMID: 6638958

Kankirawatana et al. 2006. Early progressive encephalopathy in boys and MECP2 mutations. Neurology. 67, 164–166. PMID: 16832102

Krishnaraj et al. 2017. RettBASE: Rett syndrome database update. Hum Mutat. 38, 922–931. PMID: 28544139

Laurvick et al. 2006. Rett syndrome in Australia: a review of the epidemiology. J Pediatric. 148(3):347-352. PMID: 16615965

Leonard et al. 2017. Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol. 13, 37–51. PMID: 27934853

Neul et al. 2008. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 70, 1313–1321. PMID: 18337588

Neul et al. 2010. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 68, 944–950. PMID: 21154482

Neul et al. 2019. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 180, 55–67. PMID: 30536762

Shahbazian et al. 2002. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet. 11, 115–124. PMID: 11809720

Tarquinio et al. 2015. Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis. Pediatr Neurol. 52, 585-591.e2. PMID: 25801175

Tillotson and Bird. 2019. The Molecular Basis of MeCP2 Function in the Brain. J Mol Biol. 17;S0022-2836(19)30595-9. PMID: 31629770

Return to top

Help us improve this resource by contributing your plasmids!

To get started with your deposit, please click here.